Upadacitinib, an oral selective Janus kinase 1 (JAK1) inhibitor, met its primary endpoint in the JAKPPPOT trial for palmoplantar pustulosis, according to a Medscape report.

The trial name — a deliberate play on "jackpot" — fuses "JAK" with the abbreviation PPP. Headline coverage indicates upadacitinib was tested in adults with palmoplantar pustulosis, a chronic relapsing dermatosis characterized by sterile pustules, fissuring, and erythema on the palms and soles.

Why this cohort matters

PPP sits within the broader pustular psoriasis spectrum yet runs a distinct clinical course. The condition disproportionately affects current and former smokers, often coexists with plaque psoriasis elsewhere on the body, and responds inconsistently to conventional systemic agents. Functional impairment scores routinely exceed what the limited body-surface involvement would predict.

How PPP trials score efficacy

Investigators quantify severity in PPP using the Palmoplantar Pustulosis Area and Severity Index (PPPASI), a composite of erythema, pustule counts, and desquamation scored separately for each hand and foot. Modern protocols report PPPASI-50 and PPPASI-75 response rates, alongside patient-reported instruments including the palmoplantar PSS, DLQI, and pain VAS.

The mechanism and its label

Upadacitinib selectively inhibits JAK1, modulating downstream signaling of IL-4, IL-13, IL-31, TSLP, and interferon pathways. The drug already carries FDA approvals for moderate-to-severe atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and Crohn's disease, giving clinicians familiarity with its monitoring needs — lipids, complete blood counts, infection surveillance.

Practice implications

A confirmed JAKPPPOT win would deliver a second oral systemic option for a phenotype currently served mostly by injectable biologics in the IL-17, IL-23, and IL-36 classes. Oral administration would shorten clinic infusion or injection time, suit patients with needle aversion, and may appeal to the substantial subset whose palm and sole disease coexists with limited cutaneous disease elsewhere.

What dermatologists will want next

• PPPASI-50 and PPPASI-75 delta against placebo at week 16
• Time-to-response curves and durability through week 52
• Pre-specified subgroup behavior by smoking status, prior biologic exposure, and baseline DLQI
• Adverse-event signal size — acne, herpes zoster, lab abnormalities, and any cardiovascular events
• Health-economic modeling once payer positioning and pricing emerge

Reading the headline carefully

"Hits JAKPPPOT" signals a met primary endpoint — standard sports-trial idiom — but the headline coverage stops short of disclosing specific PPPASI response rates, placebo delta, or safety signals. Those numbers will come in the full Medscape write-up and at the trial's platform presentation.

Forward-looking: The full JAKPPPOT dataset will position upadacitinib within the PPP algorithm, most plausibly as an oral second-line option alongside or behind IL-36 and IL-17/IL-23 pathway agents, contingent on subgroup behavior and the magnitude of the safety signal.